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as commonly applied, Markov models are used to deter-
mine if the new intervention is cost-effective if used in-
stead an old one at one point in the patient’s lifetime.
These models do not attempt to determine the lifetime
optimal treatment pathway for treating the disease. We
show how Markov decision models can be used to de-
velop an optimal treatment pathway, by assigning a
treatment option to each health state so as to maximize
overall net benefit. We will demonstrate how to derive
the optimal treatment pathway using dynamic program-
ming. We will present an illustrative example of the use
Markov decision model for a chronic disease such as
HIV. We will discuss some potential ethical issues that
could be raised by the optimal policies derived from
Markov decision models. We will conclude the workshop
with an interactive discussion of the benefits and draw-
backs of Markov decision models.
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OBJECTIVES: Participants will learn how to collect, an-
alyze, and use compliance data to perform per protocol
analyses that can demonstrate effectiveness and shape
models based on treatment persistence. Examples will in-
clude effectiveness for alcoholism, AIDS, cardiovascular
and mental illnesses.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who evaluate treatment outcomes, pharmacoeco-
nomic specialists who evaluate treatment costs, and other
health outcomes professionals.
Many people are negligent “partial compliers” who miss
doses regularly or intermittently despite the best inten-
tions and an understanding of the importance of taking
medication. In addition, long-term persistence with chronic
treatments is poor. These two manifestations of poor
compliance, confound assessment of drug effects, result
in poor quality medical care, and affect the overall cost of
care. Poorly compliant patients, because of their non-
response to drug treatment, advance to the uppermost
steps of stepped-care schemes, incurring needless diag-
nostic costs and treatment costs. The clinical and eco-
nomic consequences of poor compliance can range from
trivial to catastrophic, depending upon drug, disease and
its severity, and co-morbidities. Actual dose-taking and
dose-timing data collected from individuals can be linked
to efficacy parameters to stratify treatment effectiveness
based on compliance. The importance of using real-time
compliance data in outcomes analyses will be described
with examples from electronic compliance techniques.
Examples will include use of compliance data to demon-
strate value to patients and providers, as well as the phar-
maceutical industry.
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OBJECTIVES: Incorporating additional information
from the outcomes research literature (i.e. pharmacoeco-
nomics, pharmacoepidemiology, and quality of life) into
drug information resources used by clinical practitioners
presents a unique challenge. The objective of this work-
shop is to describe the complex issues involved when pro-
viding outcomes research information to clinicians who
are involved in drug therapy selection. Based on the expe-
riences of the presenters, cautionary statements about
meta analysis in outcomes research, with application to
heart failure, will be provided.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers interested in the epidemiologic, economic, and quality
of life aspects of heart failure, as well as those interested
in meta analysis and comparability of studies for clinical
practice and decision-making.
The practical applicability of outcomes research for clini-
cians represents a significant challenge. Drug information
sources could assist in making outcomes research find-
ings both succinct and “user friendly” if there were suffi-
cient literature and a means for compiling the salient
findings. The medical and pharmacy literature has an
abundant amount of information on heart failure and re-
lated treatments. Thus, it would appear that outcomes re-
search in heart failure could serve as a test case for pro-
ducing practical guidance for clinicians; however, a
number of general issues need to be addressed. How
should one objectively determine inclusion/exclusion cri-
teria for research studies? When should meta analysis be
performed and on what outcomes? When should findings
be reported for drug classes rather than individual
agents? There are also a number of questions that are
specific to heart failure. How and to what extent should
the severity of patients be used to group or stratify find-
ings? How should data on comorbidites be incorporated?
These questions will be explored in general and as part of
a heart failure case study.
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